CASI Pharmaceuticals, Inc. (CASIF) — Cost of Revenue
| Fiscal Year | Cost of Revenue | Change YoY |
|---|---|---|
| 2025 | $10.64M | -38.8% |
| 2024 | $17.39M | +25.8% |
| 2023 | $13.83M | -12.6% |
| 2022 | $15.83M | +26.0% |
| 2021 | $12.56M | +32.1% |
| 2020 | $9.51M | — |
| Fiscal Year | Cost of Revenue | Change YoY |
|---|---|---|
| 2025 | $10.64M | -38.8% |
| 2024 | $17.39M | +25.8% |
| 2023 | $13.83M | -12.6% |
| 2022 | $15.83M | +26.0% |
| 2021 | $12.56M | +32.1% |
| 2020 | $9.51M | — |